Inactive Instrument

Eidos Therapeutics, Inc.

EIDX

US28249H1041

Biotechnology & Medical Research

Eidos Therapeutics, Inc.(NasdaqGS:EIDX) dropped from Russell Small Cap Comp Growth Index

January 25, 2021 at 05:00 am

Latest news about Eidos Therapeutics, Inc.

Eidos Therapeutics, Inc.(NasdaqGS:EIDX) dropped from S&P TMI Index	27/01/21	CI
Eidos Therapeutics, Inc.(NasdaqGS:EIDX) dropped from S&P Global BMI Index	27/01/21	CI
Eidos Therapeutics, Inc. Announces Board Changes	26/01/21	CI
Eidos Therapeutics, Inc.(NasdaqGM:EIDX) dropped from NASDAQ Composite Index	26/01/21	CI
BridgeBio Pharma, Inc. completed the acquisition of remaining 36.3% stake in Eidos Therapeutics, Inc..	25/01/21	CI
Eidos Therapeutics, Inc.(NasdaqGS:EIDX) dropped from Russell 2000 Index	25/01/21	CI
Eidos Therapeutics, Inc.(NasdaqGS:EIDX) dropped from Russell 3000 Index	25/01/21	CI
Eidos Therapeutics, Inc.(NasdaqGS:EIDX) dropped from Russell 2500 Index	25/01/21	CI
Eidos Therapeutics, Inc.(NasdaqGS:EIDX) dropped from Russell 2000 Growth Index	25/01/21	CI
Eidos Therapeutics, Inc.(NasdaqGS:EIDX) dropped from Russell Small Cap Completeness Index	25/01/21	CI
Eidos Therapeutics, Inc.(NasdaqGS:EIDX) dropped from Russell Small Cap Comp Growth Index	25/01/21	CI
Eidos Therapeutics, Inc.(NasdaqGS:EIDX) dropped from Russell 3000 Growth Index	25/01/21	CI
Eidos Therapeutics, Inc.(NasdaqGS:EIDX) dropped from Russell 2500 Growth Index	25/01/21	CI
Eidos Therapeutics, Inc.(NasdaqGS:EIDX) dropped from Russell 3000E Index	25/01/21	CI
Eidos Therapeutics, Inc.(NasdaqGS:EIDX) dropped from Russell 3000E Growth Index	25/01/21	CI
Eidos Therapeutics, Inc.(NasdaqGS:EIDX) dropped from Russell 2000 Dynamic Index	25/01/21	CI
Eidos Therapeutics, Inc.(NasdaqGS:EIDX) dropped from Russell 2500 Dynamic Index	25/01/21	CI
Eidos Therapeutics, Inc.(NasdaqGS:EIDX) dropped from Russell 2000 Growth-Dynamic Index	25/01/21	CI
Eidos Therapeutics, Inc.(NasdaqGS:EIDX) dropped from Russell 2500 Growth-Dynamic Index	25/01/21	CI
Eidos Therapeutics, Inc.(NasdaqGS:EIDX) dropped from NASDAQ Biotechnology Index	25/01/21	CI
Eidos Therapeutics, Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2020	29/10/20	CI
Transcript : BridgeBio Pharma, Inc., Eidos Therapeutics, Inc. - M&A Call	05/10/20
BridgeBio Pharma, Inc. entered into a definitive agreement to acquire remaining 36.3% stake in Eidos Therapeutics, Inc. for $1 billion.	04/10/20	CI
Eidos Therapeutics, Inc. Announces Board Changes	07/08/20	CI
Eidos Therapeutics, Inc. Expects Enrollment of Patients in Its Phase 3 Clinical Trial of Acoramidis in ATTR-CM Patients	06/08/20	CI

Chart Eidos Therapeutics, Inc.

Duration

Period

More charts

Eidos Therapeutics, Inc. is a clinical stage biopharmaceutical company. The Company is focused on addressing the unmet need in diseases caused by transthyretin (TTR), amyloidosis (ATTR). It focuses on treating the disease by targeting them at their collective source by stabilizing TTR. The Company's product candidate, AG10, is an orally-administered small molecule designed to potently stabilize tetrameric TTR, thereby halting at its outset the series of molecular events that give rise to ATTR. AG10 binds and stabilizes TTR in the blood, preventing the formation of amyloid and halting progression of the disease.

Sector

Biotechnology & Medical Research

More about the company

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
VERTEX PHARMACEUTICALS INCORPORATED	+3.91%	109B
REGENERON PHARMACEUTICALS, INC.	+10.87%	105B
ARGENX SE	+1.28%	22.25B
BIONTECH SE	-13.14%	22.09B
GENMAB A/S	-7.05%	18.68B
WUXI APPTEC CO., LTD.	-38.36%	17.58B
BEIGENE, LTD.	-10.66%	16.85B
NEUROCRINE BIOSCIENCES, INC.	+3.75%	13.76B
SAREPTA THERAPEUTICS, INC.	+36.70%	12.46B

Bio Therapeutic Drugs